Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Larson

Showing results (241-250 of 383) with videos related to

Pageof 39
Sort By:
Blood Advances|February 25, 2020
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801Guido Marcucci, Susan Geyer, Kristina Laumann, et al.
Blood|June 5, 2010
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808Jonathan E Kolitz, Stephen L George, Guido Marcucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyChristian Langer, Guido Marcucci, Kelsi B Holland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2008
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyPeter Paschka, Guido Marcucci, Amy S Ruppert, et al.
Cancer|December 8, 2015
Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemiaJane E Churpek, Rafael Marquez, Barbara Neistadt, et al.
Blood Advances|October 21, 2022
The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 studyIbrahim Aldoss, Jun Yin, Anna Wall, et al.
Blood Advances|September 7, 2021
Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALLMatthew J Wieduwilt, Jun Yin, Meir Wetzler, et al.
British Journal of Haematology|November 9, 2022
Inherited cancer predisposing mutations in patients with therapy-related myeloid neoplasmsAndrew J Shih, Tomi Jun, Andrew D Skol, et al.
Blood|February 21, 2004
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemiaMikkael A Sekeres, Bercedis Peterson, Richard K Dodge, et al.
Blood|February 1, 2007
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phaseFrancois Guilhot, Jane Apperley, Dong-Wook Kim, et al.
Pageof 39

Showing results (241-250 of 383) with videos related to

Sort By:
Pageof 39
Blood Advances|February 25, 2020
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801Guido Marcucci, Susan Geyer, Kristina Laumann, et al.
Blood|June 5, 2010
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808Jonathan E Kolitz, Stephen L George, Guido Marcucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyChristian Langer, Guido Marcucci, Kelsi B Holland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2008
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyPeter Paschka, Guido Marcucci, Amy S Ruppert, et al.
Cancer|December 8, 2015
Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemiaJane E Churpek, Rafael Marquez, Barbara Neistadt, et al.
Blood Advances|October 21, 2022
The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 studyIbrahim Aldoss, Jun Yin, Anna Wall, et al.
Blood Advances|September 7, 2021
Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALLMatthew J Wieduwilt, Jun Yin, Meir Wetzler, et al.
British Journal of Haematology|November 9, 2022
Inherited cancer predisposing mutations in patients with therapy-related myeloid neoplasmsAndrew J Shih, Tomi Jun, Andrew D Skol, et al.
Blood|February 21, 2004
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemiaMikkael A Sekeres, Bercedis Peterson, Richard K Dodge, et al.
Blood|February 1, 2007
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phaseFrancois Guilhot, Jane Apperley, Dong-Wook Kim, et al.
Pageof 39